JPWO2020198466A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020198466A5 JPWO2020198466A5 JP2021557367A JP2021557367A JPWO2020198466A5 JP WO2020198466 A5 JPWO2020198466 A5 JP WO2020198466A5 JP 2021557367 A JP2021557367 A JP 2021557367A JP 2021557367 A JP2021557367 A JP 2021557367A JP WO2020198466 A5 JPWO2020198466 A5 JP WO2020198466A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- nitrogen
- oxygen
- sulfur
- partially unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025028466A JP2025087743A (ja) | 2019-03-27 | 2025-02-26 | ベータアドレナリンアゴニスト及びそれを使用する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824876P | 2019-03-27 | 2019-03-27 | |
| US62/824,876 | 2019-03-27 | ||
| US201962934482P | 2019-11-12 | 2019-11-12 | |
| US62/934,482 | 2019-11-12 | ||
| PCT/US2020/024948 WO2020198466A1 (en) | 2019-03-27 | 2020-03-26 | Beta adrenergic agonist and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025028466A Division JP2025087743A (ja) | 2019-03-27 | 2025-02-26 | ベータアドレナリンアゴニスト及びそれを使用する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022527769A JP2022527769A (ja) | 2022-06-06 |
| JPWO2020198466A5 true JPWO2020198466A5 (https=) | 2023-02-03 |
| JP2022527769A5 JP2022527769A5 (https=) | 2023-02-03 |
| JP7682097B2 JP7682097B2 (ja) | 2025-05-23 |
Family
ID=72607224
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557367A Active JP7682097B2 (ja) | 2019-03-27 | 2020-03-26 | ベータアドレナリンアゴニスト及びそれを使用する方法 |
| JP2025028466A Pending JP2025087743A (ja) | 2019-03-27 | 2025-02-26 | ベータアドレナリンアゴニスト及びそれを使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025028466A Pending JP2025087743A (ja) | 2019-03-27 | 2025-02-26 | ベータアドレナリンアゴニスト及びそれを使用する方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10947196B2 (https=) |
| EP (1) | EP3946329A4 (https=) |
| JP (2) | JP7682097B2 (https=) |
| KR (1) | KR102948270B1 (https=) |
| CN (1) | CN114007615A (https=) |
| AU (1) | AU2020248435B2 (https=) |
| BR (1) | BR112021018481A2 (https=) |
| CA (1) | CA3130291A1 (https=) |
| IL (1) | IL285759B2 (https=) |
| MX (1) | MX2021011728A (https=) |
| TW (1) | TWI886121B (https=) |
| WO (1) | WO2020198466A1 (https=) |
| ZA (1) | ZA202106625B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201903832D0 (en) | 2019-03-20 | 2019-05-01 | Atrogi Ab | New compounds and methods |
| EP4076422A4 (en) * | 2019-12-18 | 2024-01-24 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| JP7734700B2 (ja) * | 2020-06-04 | 2025-09-05 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニストの形態及び組成物 |
| EP4208159A4 (en) * | 2020-09-01 | 2024-09-25 | Curasen Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE RELIEF OF NEUROLOGICAL CONDITIONS AND DISORDERS |
| GB202015035D0 (en) | 2020-09-23 | 2020-11-04 | Atrogi Ab | New compounds and methods |
| GB202015044D0 (en) | 2020-09-23 | 2020-11-04 | Atrogi Ab | New compounds and methods |
| AU2021381373A1 (en) * | 2020-11-19 | 2023-06-29 | Curasen Therapeutics, Inc. | Beta adrenergic agonist and methods of using the same |
| CN112592280B (zh) * | 2020-12-09 | 2023-05-23 | 青岛职业技术学院 | 一种消旋沙丁胺醇的制备方法 |
| GB202113588D0 (en) | 2021-09-23 | 2021-11-10 | Atrogi Ab | New compounds and methods |
| GB202113594D0 (en) | 2021-09-23 | 2021-11-10 | Atrogi Ab | New compounds and methods |
| MX2024003481A (es) * | 2021-09-23 | 2024-04-04 | Curasen Therapeutics Inc | Agonista beta adrenergico y metodos de uso del mismo. |
| US20230157974A1 (en) * | 2021-11-15 | 2023-05-25 | Curasen Therapeutics, Inc. | Compositions and methods for improving neurological diseases and disorders |
| GB2613616A (en) * | 2021-12-09 | 2023-06-14 | Atrogi Ab | New formulations |
| GB202204085D0 (en) | 2022-03-23 | 2022-05-04 | Atrogi Ab | New compounds and methods |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| WO2023225021A1 (en) * | 2022-05-17 | 2023-11-23 | Curasen Therapeutics, Inc. | Compositions and methods for treating patients with amyotrophic lateral sclerosis (als) |
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202304604D0 (en) | 2023-03-29 | 2023-05-10 | Atrogi Ab | New compounds and medical uses thereof |
| GB202304652D0 (en) | 2023-03-29 | 2023-05-10 | Atrogi Ab | New compounds and medical uses thereof |
| GB202304661D0 (en) | 2023-03-29 | 2023-05-10 | Atrogi Ab | New compounds and medical uses thereof |
| EP4688766A1 (en) | 2023-03-29 | 2026-02-11 | Atrogi AB | Heterocycloalkyl beta-hydroxy alkyl amines for use in the treatment of hyperglycaemia and disorders characterised by hyperglycaemia |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
| GB202414472D0 (en) | 2024-10-02 | 2024-11-13 | Atrogi Ab | New compounds and uses thereof |
| GB202414491D0 (en) | 2024-10-02 | 2024-11-13 | Atrogi Ab | New compounds and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE210031C (https=) | ||||
| NL288243A (https=) | 1962-01-29 | |||
| GB979389A (en) | 1962-01-29 | 1965-01-01 | Ici Ltd | Pharmaceutical compositions containing naphthalene derivatives |
| US3975391A (en) | 1973-12-26 | 1976-08-17 | Otsuka Pharmaceutical Company Limited | 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxy-3,4-dihydrocarbostyril derivatives |
| US3952101A (en) | 1975-04-14 | 1976-04-20 | Smithkline Corporation | α-Amino methyl-5-hydroxy-2-pyridinemethanols |
| JPS596866B2 (ja) | 1975-05-22 | 1984-02-15 | オオツカセイヤク カブシキガイシヤ | ５−（（２− アルキルアミノ −１− ヒドロキシ ） アルキル ） カルボスチリルユウドウタイノセイゾウホウ |
| JPS52283A (en) | 1975-06-23 | 1977-01-05 | Otsuka Pharmaceut Co Ltd | Process for preparation of carbostyril derivatives |
| JPS5919540B2 (ja) | 1976-10-13 | 1984-05-07 | 大塚製薬株式会社 | カルボスチリル誘導体 |
| US4082847A (en) | 1976-12-06 | 1978-04-04 | Merck & Co., Inc. | Substituted aminoethanols and pharmaceutical use |
| JPS5742673A (en) | 1980-08-29 | 1982-03-10 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
| DE3115993A1 (de) | 1981-04-13 | 1982-11-11 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue indol-derivate, verfahren zu ihrer herstellung und pharmazeutische praeparate, die diese verbindungen enthalten |
| FR2528043A1 (fr) | 1982-06-03 | 1983-12-09 | Roussel Uclaf | Nouveaux derives de la 1,3-dihydro 4-/1-hydroxy-2-amino-ethyl/2h-indol-2-one, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant |
| US4460581A (en) | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
| US4853381A (en) | 1984-04-17 | 1989-08-01 | Glaxo Group Limited | Ethanolamine compounds |
| US4600710A (en) * | 1985-03-14 | 1986-07-15 | G. D. Searle & Co. | β-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives |
| EP0195397B1 (en) | 1985-03-21 | 1989-12-13 | American Cyanamid Company | M-cyanophenethanolamines as animal growth promoters and antilipogenic agents |
| US5019578A (en) | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| NZ226991A (en) | 1987-11-27 | 1992-03-26 | Merck & Co Inc | Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors |
| DE3800096A1 (de) | 1988-01-05 | 1989-07-13 | Bayer Ag | Verwendung von benzimidazolderivaten als leistungsfoerderer |
| DE3918834A1 (de) | 1989-01-26 | 1990-08-02 | Bayer Ag | Aryl- und heteroarylethanol-pyridylalkylamine, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer bei tieren und als mittel gegen adipositas |
| DE3905028A1 (de) | 1989-02-18 | 1990-08-23 | Bayer Ag | 2,4-dihalogen-6-pyridylethanolphenylisopropylamine, verfahren zu ihrer herstellung und ihre verwendung zur verschiebung des protein-fett-verhaeltnisses zugunsten von protein |
| CA2087449A1 (en) | 1990-08-13 | 1992-02-14 | Joseph L. Roba | Use of heterocyclic amino-alcohol compounds for treatment of cns diseases |
| WO1993018007A1 (fr) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Nouveau derive de carbostyrile |
| US5264459A (en) * | 1992-07-13 | 1993-11-23 | Arch Development Corporation | Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases |
| US5484612A (en) | 1993-09-22 | 1996-01-16 | The Board Of Trustees Of The Leland Stanford Junior University | Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin |
| ZA967892B (en) | 1995-09-21 | 1998-03-18 | Lilly Co Eli | Selective β3 adrenergic agonists. |
| JP2001511555A (ja) * | 1997-07-25 | 2001-08-14 | ブリティッシュ・テレコミュニケーションズ・パブリック・リミテッド・カンパニー | ソフトウエアシステムの生成 |
| JPH1186867A (ja) | 1997-09-11 | 1999-03-30 | Ricoh Co Ltd | 電極および該電極を使用した電気化学素子 |
| GB2356197A (en) | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| CZ20031012A3 (en) * | 2000-10-20 | 2004-04-14 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| AU2003251949A1 (en) | 2002-07-18 | 2004-02-09 | Vanderbilt University | Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype |
| WO2004087142A1 (en) | 2003-04-04 | 2004-10-14 | Novartis Ag | Quinoline-2-one-derivatives for the treatment of airways diseases |
| EP1684764A2 (en) | 2003-10-09 | 2006-08-02 | Inverseon, Inc. | Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |
| JP2006016314A (ja) | 2004-06-30 | 2006-01-19 | Sumitomo Chemical Co Ltd | 光学活性アミド化合物の製造方法 |
| US7528175B2 (en) | 2004-10-08 | 2009-05-05 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
| US8426475B2 (en) | 2005-04-13 | 2013-04-23 | Astion Development A/S | Treatment of connective tissue diseases of the skin |
| TW200745084A (en) | 2006-03-08 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| UY32622A (es) | 2009-05-12 | 2010-12-31 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) |
| PL2657227T3 (pl) | 2010-12-22 | 2016-09-30 | Nowa podstawiona pochodna izochinoliny | |
| WO2012163942A1 (en) * | 2011-06-01 | 2012-12-06 | Bayer Intellectual Property Gmbh | Substituted aminoimidazopyridazines |
| CN116898848A (zh) * | 2012-01-18 | 2023-10-20 | 苏州泰飞尔医药有限公司 | 治疗肺部疾病的高穿透力前药组合物和医药组合物 |
| ES2571479T3 (es) | 2012-04-20 | 2016-05-25 | Gilead Sciences Inc | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| CA2917159C (en) | 2013-07-08 | 2022-08-23 | Auspex Pharmaceuticals, Inc. | Dihydroxyphenyl neurotransmitter compounds, compositions and methods |
| AU2016295604B2 (en) | 2015-07-23 | 2019-08-01 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| GB201714745D0 (en) * | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| CN114340740A (zh) | 2019-07-01 | 2022-04-12 | 库拉森疗法公司 | β肾上腺素能激动剂及其使用方法 |
-
2020
- 2020-03-26 WO PCT/US2020/024948 patent/WO2020198466A1/en not_active Ceased
- 2020-03-26 AU AU2020248435A patent/AU2020248435B2/en active Active
- 2020-03-26 TW TW109110283A patent/TWI886121B/zh active
- 2020-03-26 MX MX2021011728A patent/MX2021011728A/es unknown
- 2020-03-26 CA CA3130291A patent/CA3130291A1/en active Pending
- 2020-03-26 EP EP20779258.1A patent/EP3946329A4/en active Pending
- 2020-03-26 IL IL285759A patent/IL285759B2/en unknown
- 2020-03-26 US US16/831,370 patent/US10947196B2/en active Active
- 2020-03-26 US US17/440,705 patent/US12448352B2/en active Active
- 2020-03-26 JP JP2021557367A patent/JP7682097B2/ja active Active
- 2020-03-26 US US16/831,285 patent/US11040944B2/en active Active
- 2020-03-26 BR BR112021018481A patent/BR112021018481A2/pt unknown
- 2020-03-26 CN CN202080023519.5A patent/CN114007615A/zh active Pending
- 2020-03-26 KR KR1020217030777A patent/KR102948270B1/ko active Active
-
2021
- 2021-06-22 US US17/355,063 patent/US20210371380A1/en not_active Abandoned
- 2021-09-08 ZA ZA2021/06625A patent/ZA202106625B/en unknown
-
2025
- 2025-02-26 JP JP2025028466A patent/JP2025087743A/ja active Pending
- 2025-09-24 US US19/339,240 patent/US20260109671A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020198466A5 (https=) | ||
| CN110396085B (zh) | 联合治疗 | |
| JP6298765B2 (ja) | 脳卒中の治療または予防に使用されるするためのフェニルカルバメート化合物 | |
| JP2018511647A5 (https=) | ||
| JP2021523200A5 (https=) | ||
| JP2018522033A5 (https=) | ||
| JP2024023383A (ja) | 社会的機能障害の治療方法 | |
| JP6270848B2 (ja) | ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下 | |
| JP2011515482A5 (https=) | ||
| KR101463653B1 (ko) | 디아민 유도체의 제조 방법 | |
| JP2011509309A5 (https=) | ||
| JP6200526B2 (ja) | 運動障害の予防又は治療用フェニルカルバメート化合物 | |
| AU2023223283A1 (en) | Di-cyclopropyl based il-17a modulators and uses thereof | |
| HK1212673A1 (zh) | 氯胺酮衍生物 | |
| JP2012532125A5 (https=) | ||
| JP2010509334A5 (https=) | ||
| JP2005514370A5 (https=) | ||
| JP2017525684A5 (https=) | ||
| RU2013113301A (ru) | Замещенные 2-оксо- и 2-тиоксо-дигидрохинолин-3-карбоксамиды в качестве модуляторов kcnq2/3 | |
| JP2025060830A5 (https=) | ||
| JPS6289681A (ja) | ５ｈｔ↓２受容体の選択的遮断剤 | |
| JP6588475B2 (ja) | 治療用化合物としての新規のｅｐ４アゴニスト | |
| RU2021131142A (ru) | Бета-адренергический агонист и способы применения | |
| JPWO2022109179A5 (https=) | ||
| JPWO2022047052A5 (https=) |